Home » Amgen: Phase III Trial Shows Denosumab Delayed Skeletal Related Events
Amgen: Phase III Trial Shows Denosumab Delayed Skeletal Related Events
Amgen announced results from a Phase III trial evaluating denosumab administered subcutaneously versus Zometa administered as an intravenous infusion in the treatment of bone metastases in 1,776 advanced cancer patients with solid tumors, excluding breast and prostate cancer, or multiple myeloma.
RTTNews
RTTNews
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May